Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer
- 311 Downloads
Salivary gland impairment following high activity radioiodine therapy of differentiated thyroid cancer (DTC) is a severe side effect. Dosimetric calculations using planar gamma camera scintigraphy (GCS) with 131I and ultrasonography (US) provided evidence that the average organ dose per administered 131I activity (ODpA) is too low to account for observed radiation damages to the salivary glands. The objective of this work was to re-estimate the ODpA using 124I PET(/CT) as a more reliable approach than 131I GCS/US.
Ten DTC patients underwent a series of six (or seven) PET scans and one PET/CT scan after administration of ∼23 MBq 124I-iodide. Volumes of interest (VOIs) drawn on the CT and serial PET images were used to determine the glandular volumes and the imaged 124I activities. To enable identical VOIs to be drawn on serial PET images, each PET was co-registered with the CT image. To correct for partial volume effect and for the artificial bias in the activity concentration due to cascading gamma coincidences occurring in 124I decay, the imaged activity was effectively corrected using isovolume recovery coefficients (RCs) based on recovery phantom measurements. A head-neck phantom, which contained 124I-filled spheres, was manufactured to validate the isovolume recovery correction method with a realistic patient-based phantom geometry and for a range of activity concentration regimes. The mean±standard deviation (range) ODpA projected for 131I was calculated using the absorbed dose fraction method.
The ODpAs (in Gy/GBq) for the submandibular and parotid glands were 0.32 ± 0.13 (0.18–0.55) and 0.31 ± 0.10 (0.13–0.46), respectively. No significant differences (p> 0.2) in the mean ODpA between 124I PET(/CT) and 131I GCS/US dosimetry was found. The validation experiment showed that the percentage deviations between RC-corrected and true activity concentrations were <10%.
124I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage.
KeywordsRadioiodine therapy Differentiated thyroid cancer Salivary gland 124I Dosimetry
- 11.Chu SYF, Ekström LP, Firestone RB. 1999. The Lund/LBNL nuclear data search. Database version 2.0 http://nucleardata.nuclear.lu.se/nucleardata/toi/
- 14.Jentzen W. Pre-therapeutic 124I PET(/CT) salivary gland dosimetry in the radioiodine therapy of differentiated thyroid carcinoma and investigation of important factors affecting the 124I quantification. Dissertation 2010, University of Duisburg-Essen, Germany.Google Scholar
- 15.Junker D, Fitschen J. Dosimetrie inkorporierter Strahlen. In: Diethelm L, Heuck F, Olsson O, Strnad F, Vieten H, Zuppinger A, editors. Handbuch der medizinischen Radiologie/Encyclopedia of medical radiology. Band/Volume 15, Teil/Part 1A. Berlin: Springer; 1980. p. 425–82.Google Scholar
- 18.Brown-Grant K. Extrathyroidal iodide concentrating mechanisms. Physiol Rev 1961;41:189–213.Google Scholar
- 19.Junqueira LC, Carneiro J. Histologie. 3rd ed. Berlin: Springer; 1991.Google Scholar